The leukotriene modifiers market size has grown strongly in recent years. It will grow from $23.54 billion in 2025 to $24.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to high prevalence of asthma and allergic rhinitis, established clinical efficacy of montelukast and related drugs, preference for non-steroidal asthma therapies, strong adoption in pediatric asthma management, availability of multiple oral dosage forms.
The leukotriene modifiers market size is expected to see strong growth in the next few years. It will grow to $30.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising global burden of respiratory and allergic diseases, increasing diagnosis rates of asthma and rhinitis, growing demand for convenient oral therapies, expansion of generic drug penetration, improved access to respiratory care in emerging markets. Major trends in the forecast period include sustained use of leukotriene modifiers in asthma maintenance therapy, growing preference for oral and pediatric-friendly formulations, increasing role of leukotriene modifiers in allergic rhinitis management, widespread availability of generic leukotriene modifier drugs, use of leukotriene modifiers as add-on therapy with inhaled corticosteroids.
The rising incidence of asthma and allergic conditions is expected to drive the growth of the leukotriene modifier market in the coming years. Asthma and allergic conditions are disorders in which the immune system overreacts to allergens, leading to inflammation, airway narrowing, and other respiratory symptoms. The prevalence of these conditions is increasing due to greater exposure to environmental pollutants, rising temperatures, changing climate patterns, and higher population density. The leukotriene modifier market supports respiratory health by offering therapies that reduce inflammation, enhance airway function, and help control symptoms associated with asthma and allergic disorders. For example, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded 474 asthma-related deaths in 2023, including 325 females and 149 males. This number was nearly the same as the 473 asthma-related deaths reported in 2022, indicating a consistent pattern in asthma mortality over the two-year period. Therefore, the increasing incidence of asthma and allergic conditions is contributing to the growth of the leukotriene modifier market.
Major companies operating in the leukotriene modifier market are focusing on the development of generic extended-release formulations to broaden treatment options, improve dosing convenience, and address the growing demand for long-acting respiratory therapies. Generic extended-release tablets are pharmaceutical formulations designed to release the active ingredient gradually over an extended duration, helping maintain stable therapeutic levels, reduce dosing frequency, and improve patient adherence compared with immediate-release formulations. For instance, in April 2023, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, expanded its product portfolio by introducing zileuton extended-release tablets in a 600 mg formulation. These tablets are indicated for the prevention and long-term management of asthma in adults and adolescents aged 12 years and older, providing sustained therapeutic effects while supporting continued use during acute asthma exacerbations.
In April 2023, SK Capital Partners LP, a US-based private investment firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. This acquisition strengthens SK Capital’s pharmaceutical portfolio by utilizing Apotex’s broad generic product range, global market presence, and experienced workforce to support growth and operational expansion. It also enhances SK Capital’s capacity to scale high-demand therapeutic segments by integrating Apotex’s established manufacturing capabilities, including the production of leukotriene modifiers such as montelukast drugs. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that manufactures leukotriene modifiers, including montelukast products.
Major companies operating in the leukotriene modifiers market are Merck And Co., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience.
North America was the largest region in the leukotriene modifiers market in 2025. The regions covered in the leukotriene modifiers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukotriene modifiers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the leukotriene modifiers market by increasing the cost of imported active pharmaceutical ingredients and excipients used in oral solid and granule formulations. These impacts have been most visible in branded products across North America and Europe, where global API sourcing is common. Asia-Pacific manufacturers have faced pricing pressure due to trade-related dependencies. However, tariffs have supported domestic manufacturing and encouraged local production of generic leukotriene modifiers, enhancing long-term supply stability.
The leukotriene modifiers market research report is one of a series of new reports that provides leukotriene modifiers market statistics, including leukotriene modifiers industry global market size, regional shares, competitors with a leukotriene modifiers market share, detailed leukotriene modifiers market segments, market trends and opportunities, and any further data you may need to thrive in the leukotriene modifiers industry. This leukotriene modifiers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leukotriene modifiers are a class of medications used to prevent and manage conditions such as asthma and allergic rhinitis (hay fever). They act by blocking the production or effects of leukotrienes, which are inflammatory chemicals in the body that cause airway narrowing, increased mucus secretion, and inflammation. By inhibiting leukotrienes, these drugs help alleviate symptoms including wheezing, breathing difficulty, and nasal congestion.
The primary drug types of leukotriene modifiers include montelukast, zafirlukast, zileuton extended release, and zileuton. Montelukast is a leukotriene receptor antagonist commonly used for asthma prevention and control, as well as for relieving seasonal allergy symptoms. These medications are available in forms such as tablets, chewable tablets, and oral granules, and are distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
The leukotriene modifiers market consists of sales of modafinil, armodafinil, amphetamine-based stimulants, fluoxetine, and sertraline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The leukotriene modifiers market size is expected to see strong growth in the next few years. It will grow to $30.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising global burden of respiratory and allergic diseases, increasing diagnosis rates of asthma and rhinitis, growing demand for convenient oral therapies, expansion of generic drug penetration, improved access to respiratory care in emerging markets. Major trends in the forecast period include sustained use of leukotriene modifiers in asthma maintenance therapy, growing preference for oral and pediatric-friendly formulations, increasing role of leukotriene modifiers in allergic rhinitis management, widespread availability of generic leukotriene modifier drugs, use of leukotriene modifiers as add-on therapy with inhaled corticosteroids.
The rising incidence of asthma and allergic conditions is expected to drive the growth of the leukotriene modifier market in the coming years. Asthma and allergic conditions are disorders in which the immune system overreacts to allergens, leading to inflammation, airway narrowing, and other respiratory symptoms. The prevalence of these conditions is increasing due to greater exposure to environmental pollutants, rising temperatures, changing climate patterns, and higher population density. The leukotriene modifier market supports respiratory health by offering therapies that reduce inflammation, enhance airway function, and help control symptoms associated with asthma and allergic disorders. For example, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded 474 asthma-related deaths in 2023, including 325 females and 149 males. This number was nearly the same as the 473 asthma-related deaths reported in 2022, indicating a consistent pattern in asthma mortality over the two-year period. Therefore, the increasing incidence of asthma and allergic conditions is contributing to the growth of the leukotriene modifier market.
Major companies operating in the leukotriene modifier market are focusing on the development of generic extended-release formulations to broaden treatment options, improve dosing convenience, and address the growing demand for long-acting respiratory therapies. Generic extended-release tablets are pharmaceutical formulations designed to release the active ingredient gradually over an extended duration, helping maintain stable therapeutic levels, reduce dosing frequency, and improve patient adherence compared with immediate-release formulations. For instance, in April 2023, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, expanded its product portfolio by introducing zileuton extended-release tablets in a 600 mg formulation. These tablets are indicated for the prevention and long-term management of asthma in adults and adolescents aged 12 years and older, providing sustained therapeutic effects while supporting continued use during acute asthma exacerbations.
In April 2023, SK Capital Partners LP, a US-based private investment firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. This acquisition strengthens SK Capital’s pharmaceutical portfolio by utilizing Apotex’s broad generic product range, global market presence, and experienced workforce to support growth and operational expansion. It also enhances SK Capital’s capacity to scale high-demand therapeutic segments by integrating Apotex’s established manufacturing capabilities, including the production of leukotriene modifiers such as montelukast drugs. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that manufactures leukotriene modifiers, including montelukast products.
Major companies operating in the leukotriene modifiers market are Merck And Co., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience.
North America was the largest region in the leukotriene modifiers market in 2025. The regions covered in the leukotriene modifiers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukotriene modifiers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the leukotriene modifiers market by increasing the cost of imported active pharmaceutical ingredients and excipients used in oral solid and granule formulations. These impacts have been most visible in branded products across North America and Europe, where global API sourcing is common. Asia-Pacific manufacturers have faced pricing pressure due to trade-related dependencies. However, tariffs have supported domestic manufacturing and encouraged local production of generic leukotriene modifiers, enhancing long-term supply stability.
The leukotriene modifiers market research report is one of a series of new reports that provides leukotriene modifiers market statistics, including leukotriene modifiers industry global market size, regional shares, competitors with a leukotriene modifiers market share, detailed leukotriene modifiers market segments, market trends and opportunities, and any further data you may need to thrive in the leukotriene modifiers industry. This leukotriene modifiers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Leukotriene modifiers are a class of medications used to prevent and manage conditions such as asthma and allergic rhinitis (hay fever). They act by blocking the production or effects of leukotrienes, which are inflammatory chemicals in the body that cause airway narrowing, increased mucus secretion, and inflammation. By inhibiting leukotrienes, these drugs help alleviate symptoms including wheezing, breathing difficulty, and nasal congestion.
The primary drug types of leukotriene modifiers include montelukast, zafirlukast, zileuton extended release, and zileuton. Montelukast is a leukotriene receptor antagonist commonly used for asthma prevention and control, as well as for relieving seasonal allergy symptoms. These medications are available in forms such as tablets, chewable tablets, and oral granules, and are distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
The leukotriene modifiers market consists of sales of modafinil, armodafinil, amphetamine-based stimulants, fluoxetine, and sertraline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Leukotriene Modifiers Market Characteristics
3. Leukotriene Modifiers Market Supply Chain Analysis
4. Global Leukotriene Modifiers Market Trends and Strategies
5. Leukotriene Modifiers Market Analysis of End Use Industries
7. Global Leukotriene Modifiers Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Leukotriene Modifiers Total Addressable Market (TAM) Analysis for the Market
9. Leukotriene Modifiers Market Segmentation
10. Leukotriene Modifiers Market Regional and Country Analysis
11. Asia-Pacific Leukotriene Modifiers Market
12. China Leukotriene Modifiers Market
13. India Leukotriene Modifiers Market
14. Japan Leukotriene Modifiers Market
15. Australia Leukotriene Modifiers Market
16. Indonesia Leukotriene Modifiers Market
17. South Korea Leukotriene Modifiers Market
18. Taiwan Leukotriene Modifiers Market
19. South East Asia Leukotriene Modifiers Market
20. Western Europe Leukotriene Modifiers Market
21. UK Leukotriene Modifiers Market
22. Germany Leukotriene Modifiers Market
23. France Leukotriene Modifiers Market
24. Italy Leukotriene Modifiers Market
25. Spain Leukotriene Modifiers Market
26. Eastern Europe Leukotriene Modifiers Market
27. Russia Leukotriene Modifiers Market
28. North America Leukotriene Modifiers Market
29. USA Leukotriene Modifiers Market
30. Canada Leukotriene Modifiers Market
31. South America Leukotriene Modifiers Market
32. Brazil Leukotriene Modifiers Market
33. Middle East Leukotriene Modifiers Market
34. Africa Leukotriene Modifiers Market
36. Leukotriene Modifiers Market Competitive Landscape and Company Profiles
37. Leukotriene Modifiers Market Other Major and Innovative Companies
40. Leukotriene Modifiers Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Leukotriene Modifiers Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses leukotriene modifiers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leukotriene modifiers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The leukotriene modifiers market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Type: Montelukast; Zafirlukast; Zileuton ER; Zileuton2) By Form: Tablets; Chewable Tablets; Oral Granules
3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Drug Stores; Online Pharmacies
Companies Mentioned: Merck And Co.; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Boehringer Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Hetero Drugs Limited; Sun Pharmaceutical Industries; Sumitomo Dainippon Pharma; Cipla Limited; Aurobindo Pharma Limited; Dr. Reddy's Laboratories; Apotex Pharmaceutical Holdings Inc.; Torrent Pharmaceuticals Ltd.; DAVA Pharmaceuticals; Alembic Pharmaceuticals Ltd.; Lannett Company; Accord Healthcare; Jubilant Life Sciences Ltd.; Aytu BioScience
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Leukotriene Modifiers market report include:- Merck And Co.
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Hetero Drugs Limited
- Sun Pharmaceutical Industries
- Sumitomo Dainippon Pharma
- Cipla Limited
- Aurobindo Pharma Limited
- Dr. Reddy's Laboratories
- Apotex Pharmaceutical Holdings Inc.
- Torrent Pharmaceuticals Ltd.
- DAVA Pharmaceuticals
- Alembic Pharmaceuticals Ltd.
- Lannett Company
- Accord Healthcare
- Jubilant Life Sciences Ltd.
- Aytu BioScience
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 24.92 Billion |
| Forecasted Market Value ( USD | $ 30.63 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
